PerkinElmer buys imaging firm VisMed

PerkinElmer has acquired Bedford, MA-based molecular imaging technology company VisEn Medical for an undisclosed sum. According to PerkinElmer exec Richard Eglen, VisEn's molecular imaging platforms complements PE's existing cellular imaging business by boosting the company's preclinical research offerings. "This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast growing space of translational biomarker reagents," Eglen said in a statement.

VisEn Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems can help researchers identify disease biomarkers and therapeutic efficacy in cells and animal models. PerkinElmer hopes that combining VisEn's technology with its existing business will lead to better screening of new drugs. VisEn's fluorescence molecular imaging systems and reagents are currently being used for cancer, inflammation, cardiovascular, skeletal and pulmonary disease research.

- here's the PerkinElmer release
- get more from Xconomy

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.